CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 49 enrolled
Drug / intervention
Carboplatin +5 moredrug
Likely dose
Paclitaxel 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02492867
NCT02492867N/ACompleted

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

University of Michigan Rogel Cancer Center·interventional·Posted Jul 9, 2015·Updated Sep 3, 2024

In Brief

A clinical study evaluating Response-driven Adaptive Radiation Therapy, Carboplatin, and 4 other interventions for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 49 participants across 2 sites.

Detailed Summary

Successful treatment of lung cancer with radiation therapy requires that the physicians determine exactly where the tumor is in the patient's body and seek to limit any unnecessary radiation to normal parts of the body. This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) ("a PET scan") and Ventilation/Perfusion Single Photon Emission Computerized Tomography (V/Q SPECT) ("a perfusion scan"), before treatment and then again during treatment to see if this scanning helps predict how well the treatment works and how well the lung functions during treatment. FDG-PET is a modern technology that uses small amounts of a radioactive glucose (FDG) to make images of the whole body and areas of active cancer. V/Q SPECT is an image mapping tool that helps assess how well the lungs are working. A Computerized Tomography (CT) will also be performed along with both of these procedures to help the researchers see clearly where the cancer or the healthy lung is located. The researchers are also doing blood and urine tests in this study to look for markers to see if this helps them determine the patient's risk of developing side effects from radiation to the lungs. The researchers hope by using these types of tests that they can have more information to help decrease the amount of toxicity patients have from this type of treatment. The researchers hope that this study will help them in the future to design radiation treatment plans that provide the best treatment for each individual patient.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 9, 2015
Enrollment StartJan 14, 2016
Primary CompletionNov 28, 2021
Study CompletionApr 21, 2022
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 11.0 years ago

Interventions

Response-driven Adaptive Radiation Therapyradiation

Carboplatindrug

AUC 2 concurrent with RT; AUC 6 during consolidation. Given IV

Paclitaxeldrug

40 mg/m\^2 IV concurrent with RT; 200 mg/m\^2 during consolidation. Given IV

FDG-PETdevice

V/Q SPECTdevice

Durvalumabdrug

10 mg/kg during consolidation. Given IV